Search

Author/Creator Xia, Lingfang

1. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. Issue 1 (11th January 2022)

Authors:
Xia, Lingfang; Peng, Jin; Lou, Ge; Pan, Mei; Zhou, Qi; Hu, Wenjing; Shi, Huirong; Wang, Li; Gao, Yunong; Zhu, Jianqing; Zhang, Yu; Sun, Rong; Zhou, Xianfeng; Wang, Quanren; Wu, Xiaohua
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Predictive value of preoperative serum squamous cell carcinoma antigen (SCC–Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study. Issue 1 (January 2020)

Authors:
Guo, Qinhao; Zhu, Jun; Wu, Yong; Wen, Hao; Xia, Lingfang; Wu, Xiaohua; Ju, Xingzhu
Journal:
European journal of surgical oncology
Issue:
Volume 46:Issue 1(2020)
Page Start:
131
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer. Issue 6 (3rd May 2021)

Authors:
Yang, Yufei; Xia, Lingfang; Wu, Yong; Zhou, Hongyu; Chen, Xin; Li, Haoran; Xu, Midie; Qi, Zihao; Wang, Ziliang; Sun, Huizhen; Cheng, Xi
Journal:
Cancer communications
Issue:
Volume 41:Issue 6(2021)
Page Start:
511
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗